Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
ConclusionsUndifferentiated pleomorphic sarcoma is an immunologically active subtype of soft tissue sarcoma, which is particularly amenable to immune checkpoint inhibitors. Pazopanib with immune checkpoint inhibitors is a well-tolerated, yet hitherto underexplored combination that may offer significant clinical benefit in advanced sarcomas —this finding warrants further evaluation in clinical trials.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer & Oncology | Clinical Trials | Docetaxel | Immunotherapy | Palliative | Sarcomas | Soft Tissue Sarcoma | Taxotere | Toxicology